Sakar Healthcare is trading at INR 979.10, up +5.25%, after Q2 net profit rose 149% year over year. - Net profit reached Rs 11.30 crore, while revenue increased 51.9% to Rs 87.41 crore year over year. - The company attributed growth to new oncology approvals, strong demand across geographies, a better oncology mix, operating leverage and disciplined cost management. - No separate October 28 company announcement explaining the move was identified; the latest results are the clearest company-specific catalyst.